Industry news: deals down, mobile ads up

Share this article:
Deal-making among pharmas fell 18% in 2011 amid a round of belt-tightening, according to UK advisory PharmaCentures, which found that licensing deals fell 16% even as M&A activity remained robust, with deal values rising 30% but benchmark payments becoming more commonplace. Oncology-based deals continue to dominate, the firm said, with Roche leading the pack, and emerging markets were a hive of activity as large pharmas sought to strengthen their operations in China and India.

US mobile adspend across  all sectors soared 89% to $1.45 billion in 2011, according to an eMarketer report which projects spending to rise to nearly $11 billion in the next five years. This year's spike was prompted in part by the rapid ascension of Google's mobile search advertising business, advertisers' growing attraction to display inventory on tablet and smartphone devices and the growing roster of mobile ad networks such as Google's AdMob, Apple's iAd and Millennial Media. Search advertising more than doubled in 2011, the firm said, to $652 million, and will top $1.28 billion for 2012. EMarketer forecast mobile display advertising spend to grow 93% to $861 million for the year and for mobile video ad spend to rise 122% to $151 million in 2012.

Share this article:

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.